For Healthcare & Life Sciences Professionals

Primary Analyst Photo	Document Information	Rate this Document
	January 6, 2006 Exploiting Unstructured Information In Pharma Harness Content To Spur Discovery And Mitigate Regulatory And Legal Risks by Laura Ramos with Bradford J. Holmes, Will McEnroe

This is an excerpt

Executive Summary

Bowing to regulatory mandate, pharmaceutical manufacturers manage unstructured information — narrative and images typically found outside relational stores — as an obligatory expense. But as the risk of regulatory and legal challenges increase, pharma firms must also exploit hidden information to spark new scientific inventions. Balancing the two requirements with an information architecture framework will empower life sciences firms to contend with both the explosion of content and the variety of technology choices available to them to tackle the challenge.

TABLE OF CONTENTS

• Unstructured Information Spells Increasing Risk To Pharma
• Create An Information Architecture To Reduce UIM Risks

RECOMMENDATIONS

• Pharma Should Leverage Information Architecture To Reduce UIM Risk

WHAT IT MEANS

• A Long UIM Road Lies Ahead For Pharma

ALTERNATIVE VIEW

• Scientific Discovery Keeps Technology Tinkering Alive
• Supplemental Material
• Related Research Documents

This is an excerpt

Buy Risk-Free

Price: US $499

Our Service Guarantee: If you are not completely satisfied with this document, notify Forrester within 24 hours of purchase for a full refund.

Already a Forrester Client?
Log in to read this document.